Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.05.23	Lilly Declares Second-Quarter 2023 Dividend (PR Newswire)
01.05.23	Lilly Says Lebrikizumab Improved 'face Or Hand Dermatitis' At 16 Weeks (RTTNews)
01.05.23	Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis (PR Newswire)
27.04.23	Lilly Q1 Profit Down, Misses View; Lifts FY23 Forecast; Stock Up In Pre Market (RTTNews)
27.04.23	Eli Lilly And Co. Q1 Profit Decreases, misses estimates (RTTNews)
27.04.23	Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum (PR Newswire)
27.04.23	Eli Lilly: Tirzepatide Achieves Up To 15.7% Weight Loss In Results From SURMOUNT-2 (RTTNews)
27.04.23	Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 (PR Newswire)
24.04.23	Lilly To Sell BAQSIMI For At Least $500 Mln In Cash (RTTNews)
24.04.23	Lilly to Divest BAQSIMI to Amphastar (PR Newswire)
17.04.23	Eli Lilly To Invest Additional $1.6 Bln, Commits 200 New Jobs At LEAP Innovation Park (RTTNews)
17.04.23	Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities (PR Newswire)
13.04.23	U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab (PR Newswire)
13.04.23	Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement (PR Newswire)
22.03.23	Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease (RTTNews)
17.03.23	Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78% (RTTNews)
14.03.23	Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
09.03.23	Lilly's Solanezumab Fails In Alzheimer's Prevention Trial (RTTNews)
08.03.23	Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease (PR Newswire)
08.03.23	Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years & Older With Type 2 Diabetes (RTTNews)
08.03.23	US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes (PR Newswire)
06.03.23	Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according t... (PR Newswire)
03.03.23	U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer (PR Newswire)
01.03.23	Eli Lilly Announces Aggressive Price Cuts For Insulins; Announces Expansion Of Insulin Value Program (RTTNews)
01.03.23	Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month (PR Newswire)
21.02.23	Lilly to Participate in Cowen's 43rd Annual Health Care Conference (PR Newswire)
13.02.23	Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh (PR Newswire)
07.02.23	Lilly to Participate in SVB Securities Global Biopharma Conference (PR Newswire)
03.02.23	Lilly to Participate in Guggenheim Oncology Conference (PR Newswire)
02.02.23	Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update (RTTNews)
02.02.23	Eli Lilly And Co. Reveals Rise In Q4 Bottom Line (RTTNews)
02.02.23	Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook (PR Newswire)
27.01.23	U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Line... (PR Newswire)
26.01.23	Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity (PR Newswire)
24.01.23	Lilly To Expand Manufacturing Facility In North Carolina (RTTNews)
24.01.23	Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park (PR Newswire)
20.01.23	Eli Lilly Announces FDA Acceptance Of SNDA For Jardiance For Chronic Kidney Disease (RTTNews)
20.01.23	US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease (PR Newswire)
20.01.23	FDA Declines To Grant Accelerated Approval To Lilly's Alzheimer's Drug (RTTNews)
20.01.23	U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab (PR Newswire)
19.01.23	Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement (PR Newswire)
04.01.23	Lilly to Participate in the J.P. Morgan Healthcare Conference (PR Newswire)
22.12.22	Lilly, ProQR To Expand Licensing And Collaboration Deal For New Genetic Medicines (RTTNews)
22.12.22	Lilly and ProQR to Expand RNA Editing Collaboration (PR Newswire)
14.12.22	Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa (PR Newswire)
13.12.22	Eli Lilly Issues FY23 Guidance; Reaffirms FY22 Outlook (RTTNews)
13.12.22	Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines (PR Newswire)
12.12.22	Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting (PR Newswire)
12.12.22	Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend (PR Newswire)
07.12.22	Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20:03		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		Schwacher Handel: SMI schliesst mit Verlusten
16:01		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
15:58		Handel in Zürich: SMI verbucht Verluste
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer

20:03

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

18:01

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

17:58

Verluste in Europa: Euro STOXX 50 letztendlich leichter

17:58

Schwacher Handel: SMI schliesst mit Verlusten

16:01

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus

15:58

Handel in Zürich: SMI verbucht Verluste